Recursion Pharmaceuticals Inc (RXRX)
Healthcare
Biotechnology
3.20 $
+6.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Recursion Pharmaceuticals Inc (RXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -81 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67 | -73 | -74 | -102 | -82 | -59 | -115 | -132 | -76 | -117 | -46 | -81 | -321 | |
| 5.5 | 7.6 | 7.6 | 7.4 | 9.0 | 7.2 | 13 | 19 | 24 | 21 | 19 | 20 | 84 | |
| 12 | 17 | 16 | 16 | 17 | 18 | 31 | 36 | 26 | 25 | 24 | 22 | 97 | |
| 12 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -10 | -4.5 | -11 | -36 | -7.3 | -0.3 | 6.0 | -5.9 | 35 | -26 | 11 | -7.8 | 12 | |
| 4.0 | 0.8 | 2.4 | 6.7 | 4.2 | 4.6 | 1.6 | 1.8 | 3.2 | 0.2 | 1.2 | 0.3 | 4.9 | |
| -2.1 | -0.3 | -2.5 | -6.7 | -4.2 | -4.6 | 275 | -7.3 | -5.8 | -2.5 | -1.2 | -0.3 | -9.9 | |
| 3.8 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | – | – | -2.3 | -2.1 | -2.0 | -2.1 | -2.1 | -2.2 | -2.2 | -8.6 | |
| 3.8 | 54 | 81 | 14 | 263 | 16 | 11 | 41 | 98 | 251 | 132 | -3.5 | 478 | |
| -66 | -20 | 4.2 | -95 | 177 | -47 | 167 | -94 | 25 | 133 | 87 | -88 | 157 | |
| -71 | -74 | -76 | -109 | -86 | -64 | -117 | -134 | -80 | -118 | -47 | -81 | -326 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.